These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 16480264)
1. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264 [TBL] [Abstract][Full Text] [Related]
2. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047 [TBL] [Abstract][Full Text] [Related]
4. Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor. Peifer C; Krasowski A; Hämmerle N; Kohlbacher O; Dannhardt G; Totzke F; Schächtele C; Laufer S J Med Chem; 2006 Dec; 49(25):7549-53. PubMed ID: 17149885 [TBL] [Abstract][Full Text] [Related]
5. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. Wissner A; Floyd MB; Johnson BD; Fraser H; Ingalls C; Nittoli T; Dushin RG; Discafani C; Nilakantan R; Marini J; Ravi M; Cheung K; Tan X; Musto S; Annable T; Siegel MM; Loganzo F J Med Chem; 2005 Dec; 48(24):7560-81. PubMed ID: 16302797 [TBL] [Abstract][Full Text] [Related]
6. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II. Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884 [TBL] [Abstract][Full Text] [Related]
7. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases. Miyazaki Y; Nakano M; Sato H; Truesdale AT; Stuart JD; Nartey EN; Hightower KE; Kane-Carson L Bioorg Med Chem Lett; 2007 Jan; 17(1):250-4. PubMed ID: 17027260 [TBL] [Abstract][Full Text] [Related]
8. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 1: SAR of the aryl region. Levy DE; Wang DX; Lu Q; Chen Z; Perumattam J; Xu YJ; Liclican A; Higaki J; Dong H; Laney M; Mavunkel B; Dugar S Bioorg Med Chem Lett; 2008 Apr; 18(7):2390-4. PubMed ID: 18334294 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416 [TBL] [Abstract][Full Text] [Related]
10. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. Harris PA; Cheung M; Hunter RN; Brown ML; Veal JM; Nolte RT; Wang L; Liu W; Crosby RM; Johnson JH; Epperly AH; Kumar R; Luttrell DK; Stafford JA J Med Chem; 2005 Mar; 48(5):1610-9. PubMed ID: 15743202 [TBL] [Abstract][Full Text] [Related]
11. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors. Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417 [TBL] [Abstract][Full Text] [Related]
12. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 2: SAR of the amine tether. Levy DE; Wang DX; Lu Q; Chen Z; Perumattam J; Xu YJ; Higaki J; Dong H; Liclican A; Laney M; Mavunkel B; Dugar S Bioorg Med Chem Lett; 2008 Apr; 18(7):2395-8. PubMed ID: 18334295 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases. Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles. Maskell L; Blanche EA; Colucci MA; Whatmore JL; Moody CJ Bioorg Med Chem Lett; 2007 Mar; 17(6):1575-8. PubMed ID: 17254788 [TBL] [Abstract][Full Text] [Related]
16. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 3: Importance of the indole orientation. Lu Q; Chen Z; Perumattam J; Wang DX; Liang W; Xu YJ; Do S; Bonaga L; Higaki J; Dong H; Liclican A; Sideris S; Laney M; Dugar S; Mavunkel B; Levy DE Bioorg Med Chem Lett; 2008 Apr; 18(7):2399-403. PubMed ID: 18337095 [TBL] [Abstract][Full Text] [Related]
17. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900 [TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of a novel series of 3-bromo-4-(1H-3-indolyl)-2,5-dihydro-1H-2,5-pyrroledione derivatives--an extended structure-activity relationship study. Mahboobi S; Eichhorn E; Winkler M; Sellmer A; Möllmann U Eur J Med Chem; 2008 Mar; 43(3):633-56. PubMed ID: 17624634 [TBL] [Abstract][Full Text] [Related]
19. Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation, structure-activity relationships and molecular modeling studies. La Regina G; Edler MC; Brancale A; Kandil S; Coluccia A; Piscitelli F; Hamel E; De Martino G; Matesanz R; Díaz JF; Scovassi AI; Prosperi E; Lavecchia A; Novellino E; Artico M; Silvestri R J Med Chem; 2007 Jun; 50(12):2865-74. PubMed ID: 17497841 [TBL] [Abstract][Full Text] [Related]
20. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]